SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to the accelerated path of its oral obesity drug, VK2735, directly into Phase 3 following positive FDA feedback, fueling community discussions about a significant short squeeze and potential lucrative partnership or acquisition in the booming GLP-1 market.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is experiencing a significant sell-off, caught in a broader market fear that AI will disrupt and displace traditional enterprise software, leading to a "Death By AI" narrative across the sector. Many investors view the sharp decline as an irrational overreaction, highlighting the company's strong fundamentals and ongoing AI integration as a major buying opportunity.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as the community hotly debates the significance of its newly operational "Eagle Line" pilot production facility and recent videos showcasing it. Bulls anticipate massive long-term upside from its solid-state battery technology, while bears criticize the lack of immediate revenue and extended commercialization timelines.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending with an imminent merger into Infleqtion (INFQ) on NYSE, fueling investor excitement around its leading quantum technology, significant NASA and DOE contracts, and strong institutional confidence. The community is actively debating its undervalued status compared to peers, with high expectations for its debut as a key player in quantum computing and sensing.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending after its Optune Pax received FDA approval for locally advanced pancreatic cancer, hailed as the first new treatment in three decades, driving community debate on its modest survival benefit, considerable commercial potential, and the stock's near-term trajectory amidst skepticism.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Energy and Transportation, Financial Products, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Energy and Transportation segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The Financial Products segment provides financing alternatives to customers and dealers for Caterpillar products and services, as well as financing for power generation facilities. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925 and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending after reporting strong earnings, with its power generation segment surging due to robust demand for turbines and gensets from AI data centers, leading to record highs and analyst upgrades. The community is actively discussing whether its current valuation is justified, as the industrial giant is now viewed by many as a key beneficiary of the ongoing AI infrastructure buildout.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly Inc is trending after reporting a significant earnings beat and robust guidance, marking its first profitable fiscal year with record revenue and gross margins. The community is actively discussing this as a potential turnaround story, driven by new leadership and increasing AI tailwinds in the edge computing sector, though some remain cautious given its past.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is trending following its stellar earnings report, initially marred by corrected erroneous news of a miss and a major short-seller retraction of prior allegations, prompting community discussion about market manipulation and a potential rebound. Investors are focused on the company's impressive growth, strong cash flow, and high profit margins, which many believe were undervalued by the initial reaction to misinformation.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is a top trending stock following strong earnings and an optimistic outlook driven by accelerating AI infrastructure orders, though initial after-hours trading reflected market concerns over gross margins. The community is debating whether the company's valuation is justified by its renewed growth and strategic positioning in the AI era, especially as its share price approaches a multi-decade high.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is actively discussed following the official launch of its JasmyChain mainnet on Arbitrum Orbit, where JASMY now serves as the custom gas token for AI and Web3 use cases within Japan's regulated ecosystem. The community is split, with bulls accumulating on conviction, emphasizing foundational utility and long-term potential, while bears highlight persistent price declines and dismiss the developments as ineffective in the current volatile market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ovid Therapeutics $OVID Position Cut by TLS Advisors LLC

TLS Advisors LLC lowered its holdings in shares of Ovid Therapeutics (NASDAQ:OVID - Free Report) by 97.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Ovid Therapeutics (NASDAQ:OVID) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered Ovid Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold"

Wall Street Zen upgraded Ovid Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

FY2025 Earnings Forecast for OVID Issued By Lifesci Capital

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities researchers at Lifesci Capital issued their FY2025 earnings estimates for Ovid Therapeutics in a research report issued on Monday, December...

Ovid Therapeutics (NASDAQ:OVID) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital assumed coverage on shares of Ovid Therapeutics in a research report on Monday. They set an "outperform" rating and a $4.00 price objective for the company...

Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated a "buy" rating and issued a $2.00 price objective on shares of Ovid Therapeutics in a research report on Monday...

Ovid Therapeutics (NASDAQ:OVID) Upgraded at Roth Capital

Roth Capital raised shares of Ovid Therapeutics to a "strong-buy" rating in a research note on Thursday...

Ovid Therapeutics Names Petra Kaufmann Chief Medical Officer

(RTTNews) - Ovid Therapeutics Inc. (OVID) on Tuesday announced the appointment of Petra Kaufmann as its chief medical officer...

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been given a consensus rating of "Buy" by the nine analysts that are presently covering the stock, Marketbeat reports. One analyst has...

William Blair Issues Pessimistic Forecast for OVID Earnings

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Stock analysts at William Blair cut their FY2025 EPS estimates for Ovid Therapeutics in a research note issued to investors on Wednesday, November...

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During on April 1, 2014 and is headquartered in New York, NY.

Ovid Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

OVID
Ovid Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OVID News

OVIDOvid Therapeutics Inc